HLVX HilleVax Inc Total Asset Value of Company

HLVX (HilleVax Corp) - company brandmark

Investment risks for HilleVax, Inc. (HLVX) are linked to market demand uncertainty and the outcome of norovirus drug trials. This chart of the total asset market value, which currently stands at 225.93, confirms a period of strategic pivot and a revision of the development portfolio. Meanwhile, high barriers to entry in the sector and patent protection create significant hurdles for competitors under strict FDA oversight.

HLVX (HilleVax, Inc.) Company Total Assets history from 06/21/2023 to 09/27/2025

Analytical breakdowns and data insights for company HilleVax Corp (HLVX)

- stock quotes and analyst forecast:
Share Price hillevax.com|HLVX - Price Target Chart
- market capitalization data:
Market Valuation HilleVax Inc.|HLVX - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share HilleVax|HLVX - Book Capitalization|Market Capitalization to Book Value Ratio hillevax.com|HLVX - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio HilleVax, Inc.|HLVX - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio HilleVax Inc.|HLVX - Company Aggregate Debts|Debts to Book Capitalization HilleVax Inc.|HLVX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings HilleVax|Quick Liquidity hillevax.com
- net income and valuation multiples indicators:
HLVX - Net Profit
Fundamental valuation:HilleVax, Inc.
Manufactured products of HilleVax, Inc.

For HilleVax, Inc. (HLVX), which is currently in the clinical trial stage for vaccines with no commercial sales, the resource base is formed exclusively through external financing. The total assets of the company, calculated inversely via ROA, reflect the aggregate volume of controlled assets and liabilities, allowing investors to assess the risk of credit overleverage in the absence of operating revenue and amid unstable cash flows.

Key competitors

Total Business Assets GILD|Aggregate Company Assets cidara.com|Novavax Inc - Total Asset Value of Company|Company Total Assets CVAC|VALN (Valneva Vaccines) - Aggregate Asset Value|Company Total Assets VIR (Vir Biotechnology, Inc.)|Company Total Assets siga.com SIGA|EBS - Aggregate Company Assets|Aggregate Asset Value AVIR (Atea Pharma)|invivyd.com (IVVD) - Aggregate Company Assets|Cumulative Company Assets Enanta Pharmaceuticals, Inc|INO (Inovio Pharmaceuticals) - Company Total Assets|Company Total Assets kalaristx.com|Cumulative Company Assets DYAI (Dyadic International)|NNVC (nanoviricides.com) - Aggregate Asset Value|Talphera Corp - Cumulative Company Assets|Cocrystal Pharma Corp - Aggregate Company Assets|Traws Therapeutics - Company Total Assets|Company Total Asset Base Dogwood Therapeutics, Inc. DWTX|Qualigen Therapeutics, Inc. (QLGN) - Aggregate Company Assets|AlloVir - Aggregate Asset Value|Cumulative Company Assets VBIV|Company Total Assets Virios|Aggregate Company Assets Vaxart, Inc. (VXRT)